A phase III study of TAK-536 (long-term use study)
Phase 3
- Conditions
- Essential hypertension
- Registration Number
- JPRN-jRCT2080220837
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
Main inclusion criteria include the following:
1.Grade I or II essential hypertension, etc.
Exclusion Criteria
Main exclusion criteria include the following:
1.Secondary hypertension, grade III hypertension, or malignant hypertension
2.Cardiac disease, cerebrovascular disorder, vascular disease, or hypertensive retinopathy
3.Hyperkalemia
4.Poorly controlled diabetes mellitus, etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie TAK-536's antihypertensive effects in essential hypertension?
How does TAK-536 compare to standard-of-care calcium channel blockers in phase III hypertension trials?
Are there biomarkers associated with TAK-536 response in patients with resistant essential hypertension?
What adverse event profiles have been reported for TAK-536 in long-term hypertension studies?
What combination therapies with TAK-536 are being explored for hypertension management by Takeda?